Cryosite Limited
CTE.ASXHealth Care
The Company provides an integrated clinical trial logistics service, biological storage and sample management service, including: the storage of cord blood stem cells for private use.
Market Data
$1.200
-0.0%$58.6M
27.9x
$0.043
1.67%
+0.2%
Latest Earnings
Trading Update - Full Year Results - 30 June 2026
13 July 2026
Cryosite delivered strong FY2026 results with revenue up 18% to $16.7m and EBITDA up 27% to $4.3m, demonstrating accelerating earnings growth outpacing revenue due to improved capacity utilization at its Ferndell Street headquarters. EBIT grew 35% to $3.4m while NPAT increased 20% to $2.3m, with margins expanding across the board. The company is well-positioned for FY2027 with completed cool room expansion and ongoing Adderley Street facility development, supported by a strong client pipeline. Key points: Revenue growth of 18% to $16.7m with EBITDA growth of 27% to $4.3m demonstrates operating leverage and improving unit economics; EBIT grew 35% to $3.4m, significantly outpacing revenue growth, indicating strong margin expansion and operational efficiency gains; EBITDA margin expanded 180 basis points to 25.7%, showing improved profitability and capacity utilization at Ferndell Street headquarters
Recent Announcements
Trading Update - Full Year Results - 30 June 2026
Cryosite delivered strong FY2026 results with revenue up 18% to $16.7m and EBITDA up 27% to $4.3m, demonstrating accelerating earnings growth outpacing revenue due to improved capacity utilization at its Ferndell Street headquarters. EBIT grew 35% to $3.4m while NPAT increased 20% to $2.3m, with margins expanding across the board. The company is well-positioned for FY2027 with completed cool room expansion and ongoing Adderley Street facility development, supported by a strong client pipeline. Key points: Revenue growth of 18% to $16.7m with EBITDA growth of 27% to $4.3m demonstrates operating leverage and improving unit economics; EBIT grew 35% to $3.4m, significantly outpacing revenue growth, indicating strong margin expansion and operational efficiency gains; EBITDA margin expanded 180 basis points to 25.7%, showing improved profitability and capacity utilization at Ferndell Street headquarters
Trading Update - Financial Year-to-Date - 30 April 2026
Cryosite Limited (ASX: CTE) reported strong financial performance for the ten months to 30 April 2026, with revenue up 22% to $13.8m and EBITDA up 28% to $3.4m, driven by growing clinical trial activity and ultra-frozen/cryogenic storage demand. The company completed capacity expansion at its Ferndell Street facility, refinanced its NAB debt facility to 2030, and is commissioning its newly acquired Adderley Street warehouse on schedule.
Appendix 4D and Half Year Accounts
Cryosite delivered strong HY26 results with revenue up 25% to $8.3M and NPAT up 36% to $1.1M, driven by broad-based growth across clinical trials, biologics and advanced therapies. The company doubled its storage capacity by acquiring a new warehouse facility in Auburn NSW for $10.1M, funded through cash and a $6.65M NAB loan facility. Key points: Strong broad-based growth across all temperature-controlled segments with operational volumes up 30% year-on-year; Ultra-Frozen and Cryogenic segment revenue increased 63% to $1.2M with EBITDA up 44%; Successfully doubled storage capacity through acquisition of Auburn warehouse facility
Get real-time alerts for CTE
Receive AI-powered earnings summaries and instant notifications when Cryosite Limited releases results.
Register Free